EMA Authorised: Dimethyl fumarate Mylan (dimethyl fumarate) — Mylan Pharmaceuticals Limited

View source ↗

Summary

Dimethyl fumarate by Mylan Pharmaceuticals Limited has been authorised for multiple sclerosis in the EU.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Dimethyl fumarate (Dimethyl fumarate)

Snippet

Status: Authorised. Therapeutic area: Multiple Sclerosis. MAH: Mylan Pharmaceuticals Limited. Decision date: 08/06/2026